Company Details

Name Adjuvantix
Year founded 2003
Category Medicine
University partner Sheffield
Biofusion shareholding 49%
Biofusion investment to date £240,000 (committed up to)

Contact Details

Contact details  Peter Grant
Adjuvantix Limited
The Bioincubator
40 Leavygreave Road
Sheffield
S3 7RD
Telephone +44 (0) 114 275 5569
E-mail petergrant@adjuvantix.co.uk
Website http://www.adjuvantix.com

Company Background

Adjuvantix intends to use proprietary adjuvants to develop a range of improved prophylactic and therapeutic vaccines. It aims to exploit this technology to develop adjuvant systems suited to a wide range of vaccine antigens, including proteins, peptides, polysaccharides and organic molecules that are designed to provide the desired antibody or cell-mediated immune response for any given clinical application.

For the non-technical

Vaccines work by injecting healthy people with the non-dangerous bit of a disease, so that the body’s immune system learns how to recognise the invading organism and kill it off. Adjuvants help stimulate the immune system‘s response to the vaccine, so the better the adjuvant, the lower the vaccination dose can be, so the vaccine is cheaper and safer.

Adjuvantix’s adjuvant is potentially 1000 times more potent than untreated adjuvants.


back